aln-ttrsc04
Nucleic acidexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Dec 26, 2022 (NCT05661916)
Timeline
Indications
Studied for
Mechanism of action
- TransthyretinANTISENSE INHIBITOR
ATTR
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068150 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07223203 | Phase 3 | Dec 31, 2025 | Alnylam Pharmaceuticals |
| NCT07052903 | Phase 3 | Jul 2, 2025 | Alnylam Pharmaceuticals |
| NCT05661916 | Phase 1 | Dec 26, 2022 | Alnylam Pharmaceuticals |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alnylam Pharmaceuticals | For profit | 3 | 3 | 2 | 2022 |
1 organizations
Page 1 / 1